Stay updated on CBDV Safety & Tolerability in ASD Clinical Trial

Sign up to get notified when there's something new on the CBDV Safety & Tolerability in ASD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CBDV Safety & Tolerability in ASD Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The site revision identifier in the footer changes from v3.8.0 to v3.8.1, while the clinical trial record remains unchanged.
    Difference
    0.1%
    Check dated 2026-11-21T11:34:03.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The clinical trial record for a Phase 2 study of cannabidivarin (CBDV) for children and young adults with autism spectrum disorder is displayed, including its termination after enrolling one participant and detailed study information.
    Difference
    43%
    Check dated 2026-11-07T11:30:21.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-10-31T11:09:04.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    An NIH-wide banner announces a transition from the term “Artificial Intelligence” to “Super Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-24T11:18:43.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T13:55:42.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    The footer revision label was updated from v3.7.0 to v3.7.1 on the error page.
    Difference
    0.2%
    Check dated 2026-10-10T14:51:33.000Z thumbnail image

Stay in the know with updates to CBDV Safety & Tolerability in ASD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CBDV Safety & Tolerability in ASD Clinical Trial page.